
Selank
Potential Benefits
- Approved in Russia for anxiety and generalized anxiety disorder
- Research suggests anxiolytic effects without sedation or cognitive impairment
- Studies indicate potential nootropic properties, including improved memory and learning
- May modulate the immune system through effects on cytokine expression
- Preclinical data suggests potential influence on BDNF expression
- Does not appear to carry addiction or tolerance risk based on available data
Recommended Starting Dose
250-500 mcg intranasally per dose
Based on published research protocols. Not a prescription.
Dosing Protocol
Typically administered as a nasal spray at 250-500 mcg per dose, 2-3 times daily. Treatment courses in Russian clinical practice run 14 days, with the option to repeat after a break. Some protocols use subcutaneous injection at similar doses.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Anxiolytic effects are often reported within the first few days of use. Cognitive benefits may develop over 1-2 weeks of consistent administration.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Generally well-tolerated in clinical settings
- Nasal irritation with intranasal administration
- Mild fatigue in some reports
- Limited long-term safety data outside Russian studies
- Potential interactions with other anxiolytic or psychoactive substances
More in Cognitive

Semax
Semax
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-10) with an added Pro-Gly-Pro C-terminal tripeptide for metabolic stability. Developed in Russia, it is approved there for conditions including stroke recovery, cognitive disorders, and peptic ulcers. It is administered intranasally.

Dihexa
Dihexa
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide derived from angiotensin IV. Developed at Washington State University by Dr. Joseph Harding, it was found to be up to 10 million times more potent than BDNF at promoting hepatocyte growth factor (HGF) signaling. Research has focused on its potential to drive synaptogenesis and cognitive enhancement.

PE-22-28
PE-22-28 (Spadin analog)
PE-22-28 is a synthetic heptapeptide derived from spadin, which itself is a fragment of the sortilin propeptide. It acts as an antagonist of the TREK-1 potassium channel, a validated target for antidepressant activity. Research suggests it may have rapid-onset antidepressant-like effects in animal models, acting within days rather than weeks.
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.